Pharmaceutical Science Advisory Committee
Stephen Byrn, PhD, who served as acting chairman during the committee's Sept. 23 meeting, is a professor of medicinal chemistry at the School of Pharmacy and Pharmacal Sciences at Purdue University (1"The Pink Sheet" Sept. 27, p. 27)
You may also be interested in...
FDA should establish a clearly defined protocol prior to entering a two-year interim study to validate individual bioequivalence for regulatory policy, FDA's Pharmaceutical Science Advisory Committee agreed at its Sept. 23 meeting.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials